Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Oct
31
Today In Oncology
OptiTROP-Lung06 A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?
How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation
Selpercatinib Sacituzumab Govitecan Show Activity in Thyroid Cancer Subtypes
ASTRO Updates Guideline on Shorter-Course Radiation Therapy for Localized Prostate Cancer
High-Risk Melanoma Personalized mRNA Vaccine Plus Immunotherapy Reduces Risk of Recurrence After Surgery
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo